Coaxil (tianeptine) in the treatment of depression
in Parkinson's disease

Levin OS.
Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(3):20-5.


Clinical evaluation of tianeptine (coaxil) efficacy and safety has been conducted in an open non-comparison study of 18 patients with Parkinson's disease (PD) with moderate and marked depressive symptoms measured by Hamilton and Beck depression scales. To the end of the 3rd month of the treatment, scores on the Hamilton Depression Scale (HAM-D) decreased by 34% and by 31% on the Beck Depression Scale (p<0.05) as compared to the baseline level. Improvement was observed in 14 out of 18 patients (77%), with decreasing of HAM-D scores by 50% and over in 8 patients (44%). An analysis of depressive symptoms structure revealed that the improvement was due to the decrease of anxiety and somatoform symptoms and, to a lesser extent, to melancholy and sleep disorders. However, a level of apathy did not change. The decrease of depression was accompanied by significant improvement of quality of life. The efficacy of coaxil was higher in patients with less marked depressive and motor symptoms, shorter disease course and less cognitive impairment. Good tolerability of coaxil was observed during the whole study. Therefore, coaxil may be recommended for treatment of depressive symptoms in patients with PD.
Rasagiline (Azilect)
Tianeptine (Stablon)
Tianeptine: structure
Depression in Parkinson's disease
Ethanol withdrawal and tianeptine
Discriminative stimulus properties
Selegiline (l-deprenyl, EMSAM etc)
Ischaemic heart disease/depression
Parkinson's Disease: some resources

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family